## Maria Caroline Vos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3167318/publications.pdf

Version: 2024-02-01

687363 839539 18 480 13 18 citations h-index g-index papers 18 18 18 840 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Impact of an Automatically Generated Cancer Survivorship Care Plan on Patient-Reported Outcomes in Routine Clinical Practice: Longitudinal Outcomes of a Pragmatic, Cluster Randomized Trial. Journal of Clinical Oncology, 2015, 33, 3550-3559.	1.6	106
2	Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study. BMC Cancer, 2015, 15, 593.	2.6	88
3	Survivorship Care Plans to inform the primary care physician: results from the ROGY care pragmatic cluster randomized controlled trial. Journal of Cancer Survivorship, 2014, 8, 595-602.	2.9	38
4	MMP-14 and CD44 in Epithelial-to-Mesenchymal Transition (EMT) in ovarian cancer. Journal of Ovarian Research, 2016, 9, 53.	3.0	33
5	Changes in internet use and wishes of cancer survivors: A comparison between 2005 and 2017. Cancer, 2020, 126, 408-415.	4.1	33
6	Improved preoperative risk stratification with CA-125 in low-grade endometrial cancer: a multicenter prospective cohort study. Journal of Gynecologic Oncology, 2019, 30, e70.	2.2	28
7	Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY Care Trial: New insights for tailored delivery. Cancer, 2019, 125, 788-797.	4.1	25
8	Oncology providers' evaluation of the use of an automatically generated cancer survivorship care plan: longitudinal results from the ROGY Care trial. Journal of Cancer Survivorship, 2014, 8, 248-259.	2.9	21
9	Plpelle Prospective ENDOmetrial carcinoma (PIPENDO) study, pre-operative recognition of high risk endometrial carcinoma: a multicentre prospective cohort study. BMC Cancer, 2015, 15, 487.	2.6	19
10	Immunohistochemical expression of MMP-14 and MMP-2, and MMP-2 activity during human ovarian follicular development. Reproductive Biology and Endocrinology, 2014, 12, 12.	3.3	18
11	A patient decision aid for riskâ€reducing surgery in premenopausal <i>BRCA1/2</i> mutation carriers: Development process and pilot testing. Health Expectations, 2018, 21, 659-667.	2.6	17
12	Cost-effectiveness of laparoscopy as diagnostic tool before primary cytoreductive surgery in ovarian cancer. Gynecologic Oncology, 2017, 146, 449-456.	1.4	15
13	The role of MMP-14 in ovarian cancer: a systematic review. Journal of Ovarian Research, 2021, 14, 101.	3.0	15
14	Limited independent prognostic value of MMP-14 and MMP-2 expression in ovarian cancer. Diagnostic Pathology, 2016, 11, 34.	2.0	10
15	Paper-Based Survivorship Care Plans May be Less Helpful for Cancer Patients Who Search for Disease-Related Information on the Internet: Results of the Registrationsystem Oncological Gynecology (ROGY) Care Randomized Trial. Journal of Medical Internet Research, 2016, 18, e162.	4.3	8
16	Polymorphisms in MMP-14 and MMP-2 genes and ovarian cancer survival. Cancer Biomarkers, 2019, 25, 233-241.	1.7	3
17	Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy. Gynecologic Oncology, 2021, 163, 371-377.	1.4	2
18	Primary Ovarian Tumors With Lymphogenic and Hematogenic Metastasis Express High MMP-14, Which Colocalizes With Highly Sulfated Chondroitin Sulfate in the Stroma. International Journal of Gynecological Pathology, 2020, 39, 184-192.	1.4	1